(MDXG) MiMedx - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 587m USD | Total Return: -44.7% in 12m

Stock Placental Allografts, Amniotic Membranes, Wound Care, Surgical Grafts
Total Rating 45
Safety 86
Buy Signal -0.84
Biotechnology +3.6
Biotechnology +4.5
Market Cap: 587m
Avg Trading Vol: 3.63M USD
ATR: 4.51%
Peers RS (IBD): 1.3
Risk 5d forecast
Volatility41.8%
Rel. Tail Risk-9.83%
Reward TTM
Sharpe Ratio-1.57
Alpha-65.41
Character TTM
Beta0.959
Beta Downside1.633
Drawdowns 3y
Max DD60.92%
CAGR/Max DD0.09
EPS (Earnings per Share) EPS (Earnings per Share) of MDXG over the last years for every Quarter: "2021-03": -0.09, "2021-06": -0.03, "2021-09": -0.04, "2021-12": 0.01, "2022-03": -0.11, "2022-06": -0.11, "2022-09": -0.09, "2022-12": -0.02, "2023-03": -0.06, "2023-06": -0.0046, "2023-09": 0.06, "2023-12": 0.32, "2024-03": 0.07, "2024-06": 0.12, "2024-09": 0.05, "2024-12": 0.07, "2025-03": 0.05, "2025-06": 0.1, "2025-09": 0.15, "2025-12": 0.14, "2026-03": 0,
EPS CAGR: 111.91%
EPS Trend: 51.1%
Last SUE: -1.87
Qual. Beats: 0
Revenue Revenue of MDXG over the last years for every Quarter: 2021-03: 59.967, 2021-06: 68.165, 2021-09: 63.074, 2021-12: 67.409, 2022-03: 58.894, 2022-06: 66.883, 2022-09: 67.689, 2022-12: 74.375, 2023-03: 71.676, 2023-06: 81.257, 2023-09: 81.712, 2023-12: 86.832, 2024-03: 84.709, 2024-06: 87.207, 2024-09: 84.057, 2024-12: 92.907, 2025-03: 88.205, 2025-06: 98.605, 2025-09: 113.725, 2025-12: 118.095, 2026-03: null,
Rev. CAGR: 20.39%
Rev. Trend: 95.2%
Last SUE: 1.72
Qual. Beats: 3
Description: MDXG MiMedx

MiMedx Group, Inc. (NASDAQ: MDXG) manufactures placental-derived allografts using its proprietary PURION® aseptic processing platform, which preserves native cytokines, chemokines and growth factors. The technology is applied to human placental membrane, umbilical cord and placental disc tissue to create sterile, ready-to-use grafts for wound care, burn treatment and a range of surgical indications.

The product lineup includes EPIFIX, EPICORD and EPIEFFECT barrier sheets for wound management, as well as AMNIOFIX and AMNIOEFFECT for orthopedic, vascular and plastic-surgery reconstructions. These offerings are sold through a direct sales force, independent agents and distributors across the United States, and the company leverages a strategic alliance with Vaporox, Inc. to broaden its wound-care reach.

In its most recent fiscal year (2023), MiMedx reported revenue of approximately $1.42 billion, a modest 4 % year-over-year increase driven by higher adoption of its placental grafts in chronic wound and surgical markets. The firm ended the year with $258 million of cash and short-term investments, and a net loss of $312 million, reflecting ongoing integration costs from recent acquisitions. The broader biotechnology and advanced wound-care sector is benefiting from an aging U.S. population and rising prevalence of diabetes, supporting a projected 5.8 % CAGR in the wound-care market through 2028.

For a deeper dive into MDXG’s valuation metrics and peer comparison, you may want to explore ValueRay’s analysis tools.

Headlines to Watch Out For
  • Placental tissue allograft sales drive revenue growth
  • Regulatory approvals impact product launch timelines
  • Healthcare reimbursement policies affect product accessibility
  • Direct sales force efficiency influences market penetration
  • Competition in wound care market pressures pricing
Piotroski VR‑10 (Strict) 6.5
Net Income: 48.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.20 > 0.02 and ΔFCF/TA -0.38 > 1.0
NWC/Revenue: 50.93% < 20% (prev 41.93%; Δ 9.00% < -1%)
CFO/TA 0.22 > 3% & CFO 74.0m > Net Income 48.6m
Net Debt (-143.6m) to EBITDA (81.3m): -1.77 < 3
Current Ratio: 4.32 > 1.5 & < 3
Outstanding Shares: last quarter (149.7m) vs 12m ago 0.45% < -2%
Gross Margin: 82.56% > 18% (prev 0.83%; Δ 8.17k% > 0.5%)
Asset Turnover: 138.0% > 50% (prev 132.2%; Δ 5.84% > 0%)
Interest Coverage Ratio: 31.01 > 6 (EBITDA TTM 81.3m / Interest Expense TTM 2.14m)
Altman Z'' 4.63
A: 0.62 (Total Current Assets 277.5m - Total Current Liabilities 64.3m) / Total Assets 342.7m
B: -0.12 (Retained Earnings -42.7m / Total Assets 342.7m)
C: 0.22 (EBIT TTM 66.5m / Avg Total Assets 303.3m)
D: -0.49 (Book Value of Equity -42.5m / Total Liabilities 86.1m)
Altman-Z'' Score: 4.63 = AA
Beneish M -2.99
DSRI: 1.13 (Receivables 75.7m/55.8m, Revenue 418.6m/348.9m)
GMI: 1.00 (GM 82.56% / 82.67%)
AQI: 0.77 (AQ_t 0.18 / AQ_t-1 0.23)
SGI: 1.20 (Revenue 418.6m / 348.9m)
TATA: -0.07 (NI 48.6m - CFO 74.0m) / TA 342.7m)
Beneish M-Score: -2.99 (Cap -4..+1) = A
What is the price of MDXG shares? As of April 06, 2026, the stock is trading at USD 3.92 with a total of 1,678,700 shares traded.
Over the past week, the price has changed by +1.55%, over one month by -17.47%, over three months by -38.07% and over the past year by -44.71%.
Is MDXG a buy, sell or hold? MiMedx has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy MDXG.
  • StrongBuy: 5
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the MDXG price?
Wallstreet Target Price 9.7 146.7%
Analysts Target Price 9.7 146.7%
MDXG Fundamental Data Overview as of 03 April 2026
P/E Trailing = 12.3438
P/E Forward = 19.5313
P/S = 1.4018
P/B = 2.2816
P/EG = 2.97
Revenue TTM = 418.6m USD
EBIT TTM = 66.5m USD
EBITDA TTM = 81.3m USD
Long Term Debt = 16.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.82m USD (from shortTermDebt, last quarter)
Debt = 22.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -143.6m USD (from netDebt column, last quarter)
Enterprise Value = 443.2m USD (586.8m + Debt 22.5m - CCE 166.1m)
Interest Coverage Ratio = 31.01 (Ebit TTM 66.5m / Interest Expense TTM 2.14m)
EV/FCF = 6.39x (Enterprise Value 443.2m / FCF TTM 69.3m)
FCF Yield = 15.64% (FCF TTM 69.3m / Enterprise Value 443.2m)
FCF Margin = 16.56% (FCF TTM 69.3m / Revenue TTM 418.6m)
Net Margin = 11.60% (Net Income TTM 48.6m / Revenue TTM 418.6m)
Gross Margin = 82.56% ((Revenue TTM 418.6m - Cost of Revenue TTM 73.0m) / Revenue TTM)
Gross Margin QoQ = 83.86% (prev 83.54%)
Tobins Q-Ratio = 1.29 (Enterprise Value 443.2m / Total Assets 342.7m)
Interest Expense / Debt = 1.80% (Interest Expense 405k / Debt 22.5m)
Taxrate = 30.31% (6.61m / 21.8m)
NOPAT = 46.3m (EBIT 66.5m * (1 - 30.31%))
Current Ratio = 4.32 (Total Current Assets 277.5m / Total Current Liabilities 64.3m)
Debt / Equity = 0.09 (Debt 22.5m / totalStockholderEquity, last quarter 256.5m)
Debt / EBITDA = -1.77 (Net Debt -143.6m / EBITDA 81.3m)
Debt / FCF = -2.07 (Net Debt -143.6m / FCF TTM 69.3m)
Total Stockholder Equity = 228.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.02% (Net Income 48.6m / Total Assets 342.7m)
RoE = 21.24% (Net Income TTM 48.6m / Total Stockholder Equity 228.7m)
RoCE = 27.10% (EBIT 66.5m / Capital Employed (Equity 228.7m + L.T.Debt 16.5m))
RoIC = 18.75% (NOPAT 46.3m / Invested Capital 247.0m)
WACC = 9.05% (E(586.8m)/V(609.4m) * Re(9.35%) + D(22.5m)/V(609.4m) * Rd(1.80%) * (1-Tc(0.30)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.56%
[DCF] Terminal Value 78.18% ; FCFF base≈63.4m ; Y1≈77.9m ; Y5≈131.6m
[DCF] Fair Price = 13.48 (EV 1.86b - Net Debt -143.6m = Equity 2.00b / Shares 148.6m; r=9.05% [WACC]; 5y FCF grow 24.47% → 3.0% )
EPS Correlation: 51.06 | EPS CAGR: 111.9% | SUE: -1.87 | # QB: 0
Revenue Correlation: 95.21 | Revenue CAGR: 20.39% | SUE: 1.72 | # QB: 3
EPS next Quarter (2026-06-30): EPS=0.02 | Chg7d=-0.001 | Chg30d=+0.002 | Revisions Net=+0 | Analysts=4
EPS current Year (2026-12-31): EPS=0.13 | Chg7d=-0.010 | Chg30d=+0.010 | Revisions Net=+0 | Growth EPS=-71.1% | Growth Revenue=-17.0%
EPS next Year (2027-12-31): EPS=0.26 | Chg7d=-0.003 | Chg30d=-0.018 | Revisions Net=+0 | Growth EPS=+98.1% | Growth Revenue=+13.1%
[Growth] Implied Growth Rate = 1.2% (Discount Rate 9.3% - Earnings Yield 8.1%)
[Growth] Growth Spread = -19.7% (Analyst -18.4% - Implied 1.2%)
External Resources
Dataroma Stockcircle